The move's timing lines up with accelerating growth, improving margins, and a rare buyback signal from a newly public fintech ...

"I've been batting beautifully in the nets. When the runs have to come, they'll come. Not out of form, definitely out of runs ...

Wondering if Tandem Diabetes Care at around $21 a share is a hidden bargain or a value trap? You are not alone, and that is exactly what we are going to unpack here. The stock has bounced 2.2% over ...